Skip to main content
. 2022 Nov 16;83(3):227–236. doi: 10.1002/pros.24454

Figure 1.

Figure 1

Patient selection schematic. mCRPC, metastatic castrate‐resistant prostate cancer; PARP, poly(ADP‐ribose) polymerase.